Chicago, IL (PRWEB) September 26, 2017 -- HumanZyme Inc., a leading supplier of novel recombinant human proteins and growth factors expressed in human cells, today announced the launch of HumanKine® Interferon gamma (IFN gamma) expressed from HEK293 cells. IFN gamma, also known as Type II interferon, protects against bacterial, viral and protozoan infections, and is produced by TH-1 or NK cells. Important research is underway on the immunomodulatory activity of IFN gamma, including stimulation of cell-based immunity and cytotoxicity. IFN gamma has been evaluated for use in a variety of clinical applications including as an anti-cancer biotherapeutic, and is FDA approved for the treatment chronic granulomatous disease (CGD) and severe, malignant osteoporosis.
According to Scott Coleridge, CEO at HumanZyme, “Recombinant human IFN-beta is the latest offering in a series of new, high-quality, HEK293-expressed cytokines that are difficult to manufacture. Using our proprietary HEK293 expression system, we are proud to be one of only a few commercial suppliers to offer tag-free recombinant human Interferon gamma expressed in human cells for research purposes. The new IFN gamma further expands our recombinant human interferon product offering to include IFN alpha 2a, IFN alpha 2b, IFN beta, and now IFN gamma.”
IFN gamma has two N-linked glycosylation sites, Asn-25 and Asn-97, on the surface of the dimer, and glycosylation is essential to its half-life in human serum and its full biological activity. Producing IFN gamma in HEK293 cells assures native human processing, glycosylation and folding of the purified protein compared to non-human bacterial and mammalian cell lines, or insect cell expression systems. HumanZyme’s HumanKine proteins are high quality, are animal-derived product free, xeno-free and carrier-free, and are available in bulk.
For more information, see our Interferon gamma product page.
About HumanZyme, Inc.
HumanZyme, Inc. is the global leader in providing highly authentic recombinant human proteins from human cells. Our process is cost-effective and scalable making our proteins suitable for the research, diagnostic, drug discovery and biopharmaceutical markets. HumanZyme leverages its proprietary engineered human cells, expression vector, and cell culture media to ensure high-yield production of recombinant proteins with native human post-translational modifications. We are a leading provider of cytokines and growth factors and a preferred outsourcing supplier of human protein production. Our products and services support a broad range of customers worldwide—from academic and government research institutions to biotechnology and pharmaceutical companies.
Brenda Wiggins, HumanZyme, Inc., http://www.humanzyme.com, +1 312.738.0127, [email protected]
Share this article